86 related articles for article (PubMed ID: 26581202)
1. A Novel Immune Marker Model Predicts Oncological Outcomes of Patients with Colorectal Cancer.
Chen Y; Yuan R; Wu X; He X; Zeng Y; Fan X; Wang L; Wang J; Lan P; Wu X
Ann Surg Oncol; 2016 Mar; 23(3):826-32. PubMed ID: 26581202
[TBL] [Abstract][Full Text] [Related]
2. A High RORγT/CD3 Ratio is a Strong Prognostic Factor for Postoperative Survival in Advanced Colorectal Cancer: Analysis of Helper T Cell Lymphocytes (Th1, Th2, Th17 and Regulatory T Cells).
Yoshida N; Kinugasa T; Miyoshi H; Sato K; Yuge K; Ohchi T; Fujino S; Shiraiwa S; Katagiri M; Akagi Y; Ohshima K
Ann Surg Oncol; 2016 Mar; 23(3):919-27. PubMed ID: 26564244
[TBL] [Abstract][Full Text] [Related]
3. OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer.
Weixler B; Cremonesi E; Sorge R; Muraro MG; Delko T; Nebiker CA; Däster S; Governa V; Amicarella F; Soysal SD; Kettelhack C; von Holzen UW; Eppenberger-Castori S; Spagnoli GC; Oertli D; Iezzi G; Terracciano L; Tornillo L; Sconocchia G; Droeser RA
Oncotarget; 2015 Nov; 6(35):37588-99. PubMed ID: 26439988
[TBL] [Abstract][Full Text] [Related]
4. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
5. Aldehyde Dehydrogenase 1 Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemotherapy Prior to Radical Hysterectomy.
Xie Q; Liang J; Rao Q; Xie X; Li R; Liu Y; Zhou H; Han J; Yao T; Lin Z
Ann Surg Oncol; 2016 Jan; 23(1):163-70. PubMed ID: 25916979
[TBL] [Abstract][Full Text] [Related]
6. Preoperative Neutrophil-to-Lymphocyte Ratio is a Better Prognostic Serum Biomarker than Platelet-to-Lymphocyte Ratio in Patients Undergoing Resection for Nonmetastatic Colorectal Cancer.
Choi WJ; Cleghorn MC; Jiang H; Jackson TD; Okrainec A; Quereshy FA
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S603-13. PubMed ID: 25900206
[TBL] [Abstract][Full Text] [Related]
7. DNA Hypermethylation of SHISA3 in Colorectal Cancer: An Independent Predictor of Poor Prognosis.
Tsai MH; Chen WC; Yu SL; Chen CC; Jao TM; Huang CY; Tzeng ST; Yen SJ; Yang YC
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1481-9. PubMed ID: 25968618
[TBL] [Abstract][Full Text] [Related]
8. CEA change after neoadjuvant chemotherapy including bevacizumab and clinical outcome in patients undergoing liver resection for colorectal liver metastases.
Stremitzer S; Stift J; Graf A; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
Ann Surg Oncol; 2015 Apr; 22(4):1315-23. PubMed ID: 25323471
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis-Related Markers and Prognosis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer.
de Cuba EM; de Hingh IH; Sluiter NR; Kwakman R; Coupé VM; Beliën JA; Verwaal VJ; Meijerink WJ; Delis-van Diemen PM; Bonjer HJ; Meijer GA; Te Velde EA
Ann Surg Oncol; 2016 May; 23(5):1601-8. PubMed ID: 26727921
[TBL] [Abstract][Full Text] [Related]
10. Protocadherin 10 suppresses tumorigenesis and metastasis in colorectal cancer and its genetic loss predicts adverse prognosis.
Jao TM; Tsai MH; Lio HY; Weng WT; Chen CC; Tzeng ST; Chang CY; Lai YC; Yen SJ; Yu SL; Yang YC
Int J Cancer; 2014 Dec; 135(11):2593-603. PubMed ID: 24740680
[TBL] [Abstract][Full Text] [Related]
11. Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases.
Margonis GA; Spolverato G; Kim Y; Karagkounis G; Choti MA; Pawlik TM
Ann Surg Oncol; 2015 Dec; 22(13):4158-65. PubMed ID: 26077912
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of the lymph node ratio in stage IV colorectal cancer patients who have undergone curative resection.
Ozawa T; Ishihara S; Nishikawa T; Tanaka T; Tanaka J; Kiyomatsu T; Hata K; Kawai K; Nozawa H; Kanazawa T; Kazama S; Yamaguchi H; Sunami E; Kitayama J; Watanabe T
Ann Surg Oncol; 2015 May; 22(5):1513-9. PubMed ID: 25398278
[TBL] [Abstract][Full Text] [Related]
13. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
[TBL] [Abstract][Full Text] [Related]
15. Stratification of chemotherapy-treated stage III colorectal cancer patients using multiplexed imaging and single-cell analysis of T-cell populations.
Stachtea X; Loughrey MB; Salvucci M; Lindner AU; Cho S; McDonough E; Sood A; Graf J; Santamaria-Pang A; Corwin A; Laurent-Puig P; Dasgupta S; Shia J; Owens JR; Abate S; Van Schaeybroeck S; Lawler M; Prehn JHM; Ginty F; Longley DB
Mod Pathol; 2022 Apr; 35(4):564-576. PubMed ID: 34732839
[TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of tryptophanyl-tRNA synthetase in colorectal cancer.
Ghanipour A; Jirström K; Pontén F; Glimelius B; Påhlman L; Birgisson H
Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):2949-56. PubMed ID: 19900940
[TBL] [Abstract][Full Text] [Related]
17. The prognostic significance and relationship with body composition of CCR7-positive cells in colorectal cancer.
Malietzis G; Lee GH; Bernardo D; Blakemore AI; Knight SC; Moorghen M; Al-Hassi HO; Jenkins JT
J Surg Oncol; 2015 Jul; 112(1):86-92. PubMed ID: 26179425
[TBL] [Abstract][Full Text] [Related]
18. Inverse effect of mucinous component on survival in stage III colorectal cancer.
Ooki A; Akagi K; Yatsuoka T; Asayama M; Hara H; Yamamoto G; Nishimura Y; Yamaguchi K
J Surg Oncol; 2014 Dec; 110(7):851-7. PubMed ID: 25111953
[TBL] [Abstract][Full Text] [Related]
19. Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.
Kozak MM; von Eyben R; Pai J; Vossler SR; Limaye M; Jayachandran P; Anderson EM; Shaffer JL; Longacre T; Pai RK; Koong AC; Chang DT
J Clin Pathol; 2015 May; 68(5):341-5. PubMed ID: 25681512
[TBL] [Abstract][Full Text] [Related]
20. Association between GWAS-identified genetic variations and disease prognosis for patients with colorectal cancer.
Kang BW; Jeon HS; Chae YS; Lee SJ; Park JY; Choi JE; Park JS; Choi GS; Kim JG
PLoS One; 2015; 10(3):e0119649. PubMed ID: 25799222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
